open access

Vol 9, No 6 (2020)
Research paper
Published online: 2020-09-30
Get Citation

Plasma microRNA-192 expression as a potential biomarker of diabetic kidney disease in patients with type 2 diabetes mellitus

Talaat Abd El Fattah Abdelaty, Eman Yousef Morsy, Eman Tayae El-Sayed, Shimaa Mohamed El-Rahmany, Sameh Aldesoky Anwar Lashen
DOI: 10.5603/DK.2020.0045
·
Clinical Diabetology 2020;9(6):454-460.

open access

Vol 9, No 6 (2020)
ORIGINAL ARTICLES
Published online: 2020-09-30

Abstract

Background. Albuminuria is an early clinical indicator of diabetic kidney disease (DKD). However, it has several limitations. The aim of this study was to evaluate the plasma microRNA-192 (miRNA-192) expression and its diagnostic performance in patients with type 2 diabetes mellitus (T2DM) and DKD.
Methods. In this case-control study, 75 subjects were included into 3 groups: group (1): 20 patients with T2DM and UACR (urinary albumin creatinine ratio) < 30 mg/gm, group (2): 30 patients with T2DM and ACR ≥ 30 mg/gm, and group (3): 25 healthy controls. Patients were recruited from the outpatient clinic of the Diabetes unit at our institution. Real-Time Quantitative Reverse Transcription PCR was used to assess plasma miRNA-192 expression.
Results. Plasma miRNA-192 was significantly higher in T2DM patients with DKD compared to those with normal UAE. Additionally, in patients with T2DM, plasma miRNA-192 was positively correlated with UACR. The ROC curve analysis for miRNA-192 plasma expression in patients with T2DM, revealed that miRNA-192 had a good diagnostic performance (AUC = 0.778) to define T2DM patients with DKD.
Conclusion. Plasma expression of miRNA-192 was able to discriminate increased UAE among patients with T2DM; suggesting a promising role for miRNA-192 as a potential biomarker for DKD.

Abstract

Background. Albuminuria is an early clinical indicator of diabetic kidney disease (DKD). However, it has several limitations. The aim of this study was to evaluate the plasma microRNA-192 (miRNA-192) expression and its diagnostic performance in patients with type 2 diabetes mellitus (T2DM) and DKD.
Methods. In this case-control study, 75 subjects were included into 3 groups: group (1): 20 patients with T2DM and UACR (urinary albumin creatinine ratio) < 30 mg/gm, group (2): 30 patients with T2DM and ACR ≥ 30 mg/gm, and group (3): 25 healthy controls. Patients were recruited from the outpatient clinic of the Diabetes unit at our institution. Real-Time Quantitative Reverse Transcription PCR was used to assess plasma miRNA-192 expression.
Results. Plasma miRNA-192 was significantly higher in T2DM patients with DKD compared to those with normal UAE. Additionally, in patients with T2DM, plasma miRNA-192 was positively correlated with UACR. The ROC curve analysis for miRNA-192 plasma expression in patients with T2DM, revealed that miRNA-192 had a good diagnostic performance (AUC = 0.778) to define T2DM patients with DKD.
Conclusion. Plasma expression of miRNA-192 was able to discriminate increased UAE among patients with T2DM; suggesting a promising role for miRNA-192 as a potential biomarker for DKD.

Get Citation

Keywords

ttype 2 diabetes, diabetic kidney disease, albuminuria, microRNA, microRNA-192

About this article
Title

Plasma microRNA-192 expression as a potential biomarker of diabetic kidney disease in patients with type 2 diabetes mellitus

Journal

Clinical Diabetology

Issue

Vol 9, No 6 (2020)

Article type

Research paper

Pages

454-460

Published online

2020-09-30

DOI

10.5603/DK.2020.0045

Bibliographic record

Clinical Diabetology 2020;9(6):454-460.

Keywords

ttype 2 diabetes
diabetic kidney disease
albuminuria
microRNA
microRNA-192

Authors

Talaat Abd El Fattah Abdelaty
Eman Yousef Morsy
Eman Tayae El-Sayed
Shimaa Mohamed El-Rahmany
Sameh Aldesoky Anwar Lashen

References (31)
  1. Saeedi P, Petersohn I, Salpea P, et al. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157: 107843.
  2. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014; 37(10): 2864–2883.
  3. Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014; 37(1): 226–234.
  4. MacIsaac RJ, Panagiotopoulos S, McNeil KJ, et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004; 27(1): 195–200.
  5. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015; 313(8): 837–846.
  6. Caramori ML, Kim Y, Huang C, et al. Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes. 2002; 51(2): 506–513.
  7. Najafian B, Crosson JT, Kim Y, et al. Glomerulotubular junction abnormalities are associated with proteinuria in type 1 diabetes. J Am Soc Nephrol. 2006; 17(4 Suppl 2): S53–S60.
  8. Rossing P, Hougaard P, Parving HH. Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int. 2005; 68(4): 1446–1450.
  9. Dave VP, Ngo TA, Pernestig AK, et al. MicroRNA amplification and detection technologies: opportunities and challenges for point of care diagnostics. Lab Invest. 2019; 99(4): 452–469.
  10. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30): 10513–10518.
  11. Chen Xi, Ba Yi, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10): 997–1006.
  12. Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol. 2013; 9(9): 513–521.
  13. Ma X, Lu C, Lv C, et al. The Expression of miR-192 and Its Significance in Diabetic Nephropathy Patients with Different Urine Albumin Creatinine Ratio. J Diabetes Res. 2016; 2016: 6789402.
  14. American Diabetes Association, American Diabetes Association, American Diabetes Association. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2019; 42(Suppl 1): S13–S28.
  15. American Diabetes Association. 11. Microvascular Complications and Foot Care: . Diabetes Care. 2019; 42(Suppl 1): S124–S138.
  16. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27(6): 1487–1495.
  17. Kantharidis P, Hagiwara S, Brennan E, et al. Study of microRNA in diabetic nephropathy: isolation, quantification and biological function. Nephrology (Carlton). 2015; 20(3): 132–139.
  18. Hu C, Sun L, Xiao L, et al. Insights into the Mechanisms Involved in the Expression and Regulation of Extracellular Matrix Proteins in Diabetic Nephropathy. Curr Med Chem. 2015; 22(24): 2858–2870.
  19. Sun Y, Koo S, White N, et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 2004; 32(22): e188.
  20. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007; 104(9): 3432–3437.
  21. Kato M, Arce L, Wang M, et al. A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells. Kidney Int. 2011; 80(4): 358–368.
  22. Putta S, Lanting L, Sun G, et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol. 2012; 23(3): 458–469.
  23. Krupa A, Jenkins R, Luo DD, et al. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol. 2010; 21(3): 438–447.
  24. Ruiz MA, Chakrabarti S. MicroRNAs: the underlying mediators of pathogenetic processes in vascular complications of diabetes. Can J Diabetes. 2013; 37(5): 339–344.
  25. Ahmed G, Saadi G, Meligi AEl, et al. Evaluation of microRNA-192 in patients with diabetic nephropathy. Egypt J Intern Med. 2019; 31(2): 122.
  26. Chien HY, Chen CY, Chiu YH, et al. Differential microRNA Profiles Predict Diabetic Nephropathy Progression in Taiwan. Int J Med Sci. 2016; 13(6): 457–465.
  27. Jia Y, Guan M, Zheng Z, et al. miRNAs in Urine Extracellular Vesicles as Predictors of Early-Stage Diabetic Nephropathy. J Diabetes Res. 2016; 2016: 7932765.
  28. Al-Kafaji G, Al-Muhtaresh HA. Expression of microRNA‑377 and microRNA‑192 and their potential as blood‑based biomarkers for early detection of type 2 diabetic nephropathy. Mol Med Rep. 2018; 18(1): 1171–1180.
  29. El-Monem A, Mahfouz M, Mohamed M. Microrna 192 Gene Expression in Type II Diabetic Nephropathy. The Egyptian Journal of Hospital Medicine. 2017; 68(1): 885–893.
  30. Houlihan CA, Tsalamandris C, Akdeniz A, et al. Albumin to creatinine ratio: a screening test with limitations. Am J Kidney Dis. 2002; 39(6): 1183–1189.
  31. Chudleigh RA, Dunseath G, Evans W, et al. How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes? Diabetes Care. 2007; 30(2): 300–305.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl